One of the global leaders in manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Fundamentally sound with good ROCE & ROE of around 19%
Available at fair value with a forward PE of approx 7.5 whereas Sector PE is at 25.5
Debt to Equity is 0.40 due to capacity expansion.
Highest ever operating profit in FY 2022-23
Technically price is near trendline support, expecting break of trendline support towards 250 levels according to the falling wedge pattern highlighted.
Accumulate around 250 levels in the green zone for the following targets:
Short term target @ 400 (60% ROI with 6:1 R:R)
Mid term target @ 525 (110% ROI with 11:1 R:R)
Long term target @ 650 (160% ROI with 16:1 R:R)
Stop Loss below 225 (Optional)
Do your own due diligence before taking any action.
Peace!!
Fundamentally sound with good ROCE & ROE of around 19%
Available at fair value with a forward PE of approx 7.5 whereas Sector PE is at 25.5
Debt to Equity is 0.40 due to capacity expansion.
Highest ever operating profit in FY 2022-23
Technically price is near trendline support, expecting break of trendline support towards 250 levels according to the falling wedge pattern highlighted.
Accumulate around 250 levels in the green zone for the following targets:
Short term target @ 400 (60% ROI with 6:1 R:R)
Mid term target @ 525 (110% ROI with 11:1 R:R)
Long term target @ 650 (160% ROI with 16:1 R:R)
Stop Loss below 225 (Optional)
Do your own due diligence before taking any action.
Peace!!
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.